GINA NATALIE WOODS MD
Prescription History 1467401521
Internal Medicine in Chula Vista, CA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GINA NATALIE WOODS MD, an active Internal Medicine specialist practicing in Chula Vista, CA. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 484 documented patient claims. Among these therapy options, the most frequently utilized medication is Alendronate Sodium, which accounts for 201 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other CA PrescribersVs. CA Avg |
|---|---|---|---|
| Alendronate Sodium | 201 | $13.27 | ▲ More than typical |
About Alendronate Sodium: Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Show more ▾ Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates. A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis. In 2023, this provider wrote 201 Medicare prescriptions for Alendronate Sodium, about 3.5 times the volume of the typical California prescriber of this medication (58). Medicare paid an average of $13.27 per fill, versus $12.46 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 523.7 30-Day Fills standardized to 30-day supplies 15,697 Days of Medication total across all patients in 2023 | |||
| TymlosAbaloparatide | 108 | $2,748.51 | ▲ More than typical |
About Tymlos: Abaloparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Show more ▾ It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication should not be used for children or young adults whose bones are still growing. In 2023, this provider wrote 108 Medicare prescriptions for Tymlos, about 4.3 times the volume of the typical California prescriber of this medication (25). Medicare paid an average of $2,748.51 per fill, versus $2,660.67 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 116 30-Day Fills standardized to 30-day supplies 3,480 Days of Medication total across all patients in 2023 | |||
| ForteoTeriparatide | 103 | $4,390.92 | ▲ More than typical |
About Forteo: Teriparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Show more ▾ It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication is not recommended for use in children or young adults whose bones are still growing. A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995) In 2023, this provider wrote 103 Medicare prescriptions for Forteo, about 4 times the volume of the typical California prescriber of this medication (26). Medicare paid an average of $4,390.92 per fill, versus $3,917.98 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 103.9 30-Day Fills standardized to 30-day supplies 2,932 Days of Medication total across all patients in 2023 | |||
| Raloxifene Hcl | 21 | $57.49▼ below CA avg | ▼ Less than typical |
About Raloxifene Hcl: Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. Show more ▾ It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease. A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. In 2023, this provider wrote 21 Medicare prescriptions for Raloxifene Hcl, about 64% of the volume of the typical California prescriber of this medication (33). Medicare paid an average of $57.49 per fill, versus $100.17 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 57 30-Day Fills standardized to 30-day supplies 1,710 Days of Medication total across all patients in 2023 | |||
| Teriparatide | 20 | $2,786.72 | ≈ Typical |
About Teriparatide: Teriparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Show more ▾ It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication is not recommended for use in children or young adults whose bones are still growing. A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995) In 2023, this provider wrote 20 Medicare prescriptions for Teriparatide, about the same volume as the typical California prescriber of this medication (18). Medicare paid an average of $2,786.72 per fill, versus $2,762.19 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 20.1 30-Day Fills standardized to 30-day supplies 590 Days of Medication total across all patients in 2023 | |||
| Risedronate Sodium | 16 | $109.91▼ below CA avg | ▼ Less than typical |
About Risedronate Sodium: Risedronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Show more ▾ Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Risedronate belongs to a class of medications called bisphosphonates. A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION. In 2023, this provider wrote 16 Medicare prescriptions for Risedronate Sodium, about 70% of the volume of the typical California prescriber of this medication (23). Medicare paid an average of $109.91 per fill, versus $111.88 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 43 30-Day Fills standardized to 30-day supplies 1,288 Days of Medication total across all patients in 2023 | |||
| ProliaDenosumab | 15 | $1,539.92 | ▼ Less than typical |
About Prolia: Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Show more ▾ Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone. A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS. In 2023, this provider wrote 15 Medicare prescriptions for Prolia, about a third of the volume of the typical California prescriber of this medication (39). Medicare paid an average of $1,539.92 per fill, versus $1,523.14 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 90 30-Day Fills standardized to 30-day supplies 2,700 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for GINA NATALIE WOODS MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Internal Medicine prescribing approach at this Chula Vista, CA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among CA prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
